Drug Trial Radar · NCT03529136
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
Last checked: Nov 19, 2026Latest source record: May 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
252
Planned (sponsor's estimate)
Start
Jun 1, 2018
Primary completion
Dec 31, 2019
Study completion Apr 30, 2020
Sponsor
- Lead sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Public Health Clinical Center; First Affiliated Hospital of Fujian Medical University; Yantai Hospital for Infectious Diseases; The Second Affiliated Hospital of Chongqing Medical University; Jinan Hospital for Infectious Diseases
- First posted
- May 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Decompensated liver cirrhosis is one of the life-threatening complication of chronic liver disease. Liver transplantation currently is the only effective method that can improve the survival of these patients. However, the severe shortage of donor livers, high cost, and potential serious complications have restricted the availability of liver transplantation.Umbilical cord mesenchymal stem cells (UC-MSC) has been generally shown to be safe and effective for liver diseases in some pre-clinical and clinical studies. This study aim to evaluate the safety and efficiency of human umbilical cord mesenchymal stem cell transfusion in patients with decompensated liver cirrhosis, and explore the best protocol of MSC transfusion.
Conditions
- Decompensated Liver Cirrhosis
Interventions
UC-MSCBiological
Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall survivalTime frame: one year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.